Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Treasury Shares (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Treasury Shares for 12 consecutive years, with $7.1 million as the latest value for Q4 2025.

  • Quarterly Treasury Shares rose 33.96% to $7.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.1 million through Dec 2025, up 33.96% year-over-year, with the annual reading at $7.1 million for FY2025, 33.96% up from the prior year.
  • Treasury Shares for Q4 2025 was $7.1 million at Myriad Genetics, down from $7.5 million in the prior quarter.
  • The five-year high for Treasury Shares was $7.6 million in Q2 2025, with the low at $3.1 million in Q4 2021.
  • Average Treasury Shares over 5 years is $4.9 million, with a median of $4.7 million recorded in 2023.
  • The sharpest move saw Treasury Shares surged 78.95% in 2021, then fell 8.93% in 2025.
  • Over 5 years, Treasury Shares stood at $3.1 million in 2021, then grew by 19.35% to $3.7 million in 2022, then rose by 18.92% to $4.4 million in 2023, then increased by 20.45% to $5.3 million in 2024, then skyrocketed by 33.96% to $7.1 million in 2025.
  • According to Business Quant data, Treasury Shares over the past three periods came in at $7.1 million, $7.5 million, and $7.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.